Interview with the Innovators

Clinical Pathways in Multiple Myeloma

Interview with the Innovators
Multiple Myeloma Education
Videos

Featuring:

Laura R. Bobolts, PharmD, BCOP
Senior Vice President, Clinical Strategy and Growth
OncoHealth
Pompano Beach, FL
Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS
Director, Pharmacy Operations
Florida Cancer Specialists & Research Institute
Tampa, FL
Hakan Kaya, MD
Hematologic Oncologist and Senior Partner, Cancer Care Northwest
Director, Inland Northwest Myeloma/Lymphoma & Transplant Program
Clinical Professor, Elson S. Floyd College of Medicine, Washington State University
Clinical Professor of Medicine, University of Washington School of Medicine
Spokane, WA
Lisa Raff, PharmD, MSPharm, BCPS, BCOP
Vice President, Pharmacy Services
OneOncology
Nashville, TN
Yonatan Resnick, PharmD
Director, Pharmacy Clinical Services
New England Cancer Specialists
Scarborough, ME

In this sixth installment, Hakan Kaya, MD, Lisa Raff, PharmD, MSPharm, BCPS, BCOP, and Laura Bobolts, PharmD, BCOP, discuss the importance of clinical pathways in multiple myeloma treatment as well as their development.

Related Articles

Importance of Hospital Partnerships for Bispecific Agent Implementation
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
Interview with the Innovators, Multiple Myeloma
Videos
Read Article
EHR Implementation of Bispecific Agents for Multiple Myeloma
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
Interview with the Innovators, Multiple Myeloma, Bispecific Antibodies
Videos
Read Article
Total Cost of Care for Bispecific Agents in Multiple Myeloma
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
Interview with the Innovators, Bispecific Antibodies
Videos
Read Article
Payer Policy Development for Bispecific Agents in Multiple Myeloma
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
Interview with the Innovators, Bispecific Antibodies
Videos
Read Article
REMS Operational Considerations
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
Interview with the Innovators
Videos
Read Article
Adopting Bispecific Agents for Multiple Myeloma into Practice
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
Interview with the Innovators
Videos
Read Article
Team Education for Bispecific Usage in Multiple Myeloma
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
Interview with the Innovators, Bispecific Antibodies
Videos
Read Article
Transitions of Care in Multiple Myeloma Patients
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
Interview with the Innovators
Videos
Read Article
Deciding Between Triplet Therapy for the Treatment of Pancreatic Cancer: NALIRIFOX and FOLFIRINOX
By Tanios S. Bekaii-Saab, MD; Shubham Pant, MD; Michael Pishvaian, MD, PhD
Interview with the Innovators
Videos
Read Article

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

Subscribe
Amplity
© Amplity, Inc. All Rights Reserved. Privacy Policy.

We Value Your Feedback! Tell Us How You Consume Content

Your feedback will help us tailor our content to better meet your needs and preferences.

*First Name
*Last Name
*Email
*What's your favorite format for experiencing our content?